OLBAS FOR CHILDREN - Summary of medicine characteristics

1 NAME OF THE MEDICINAL PRODUCT

2.   QUALITATIVE AND QUANTITATIVE COMPOSITION

4.1.   Therapeutic indications

4.2 Posology and method of administration

For inhalation use.

Children aged 3 months to 2 years: Sprinkle 4 drops on to a tissue placed out of the child’s reach.

Children aged 2 years and over: Sprinkle 8 to 12 drops on to a handkerchief, or add to hot water and inhale the vapours.

Not recommended for babies under 3 months old.

Do not use for topical application.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients.

4.4 Special warnings and precautions for use

Do not allow oil to remain in contact with skin for extended periods.

If symptoms worsen or do not improve after 7 days, a doctor should be contacted.

Incorrect use or accidental exposure to Olbas for Children may be harmful. If the product is accidentally put into the nose or swallowed the patient should seek immediate medical advice.

If the product gets into the eyes or comes into direct contact with the surface of the eye(s) the patient should wash the eye(s) thoroughly and seek immediate medical advice.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Pregnancy and lactation

There are no or limited amount of data from the use of Olbas For Children in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Olbas For Children should not be used during pregnancy unless potential benefits outweigh any risks.

It is unknown whether Olbas For Children /metabolites are excreted in human or animal milk. However, at therapeutic doses of Olbas For Children no effects on the breastfed newborns/infants are anticipated. Nevertheless it is not recommended that Olbas For Children be used during breast feeding.

4.7 Effects on ability to drive and use machines

Olbas For Children has no influence on the ability to drive and use machines.

4.8 Undesirable effects

No undesirable effects are likely with this product because of the low concentrations of the active ingredients. However, local hypersensitivity, contact dermatitis and irritant effects of Levomenthol and Clove Oil are listed in the literature. Methyl Salicylate may cause heartburn, wheezing, dyspnoea and the worsening of asthma.

4.9 Overdose

Reports of an overdose by inhalation of 5 ml Olbas Oil have been said to cause ataxia, confusion, euphoria, nystagmus and diplopia.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other Cold Combination Preparations, ATC code: R05X

Cajuput Oil, Clove Oil, Eucalyptus Oil, Juniper Oil and Mint Oil, Partly Dementholised render secretions more fluid and relieve congestion. Levomenthol relieves symptoms of bronchitis and sinusitis. Methyl Salicylate has analgesic properties.

5.2 Pharmacokinetic properties

The product is intended for local effect on the oropharynx.

Excretion of essential oils takes place through the lungs, skin and kidneys. After absorption, Levomenthol is excreted in the urine and bile as glucuronide.

5.3 Preclinical safety data

Clove Oil, Eucalyptus Oil, Juniper Oil and Levomenthol are mild to moderate irritants of human skin. Clove Oil and Mint Oil, Partly Dementholised are irritant to mucous membranes at concentrations >3%. There are no other non-clinical data available that are of relevance to the prescriber that are not mentioned in other sections of the Summary of Product Characteristics.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Isopropyl Myristate

Orange Fragrance 170594

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Packaged into 10 ml, 12 ml, 15 ml, 20 ml, 25 ml, 28 ml or 30 ml amber glass bottles (Ph. Eur. type III glass) fitted with plastic dropper applicator and polypropylene tamper evident screw caps.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

G. R. Lane Health Products Limited

Sisson Road

Gloucester

GL2 0GR

United Kingdom

Tel: +44 (0)1452 524012

Fax: +44 (0)1452 507930

Email: info@lanesheal­th.com